Researchers from Uganda have discovered a new SARS-CoV-2 variant out of that eastern African nation. With new sub-lineages called A.23 and A.23.1 encoding replacements in the novel coronavirus spike protein, nsp6, ORF8 and ORF9 along with A.23.1 this is now a major strain observable in Kampala, Uganda. While no one can be certain what the impact of this new strain is, scientists are monitoring this situation carefully. The needful and necessary—assess the consequences of the spike protein morphing for vaccine efficacy. Also another new variant known as B1.525 has been identified in North America as identified in UK genome sequencing.
Apparently, the B1.525 strain is under investigation in America and Canada. It is perhaps associated with the variant coupled with travel to Nigeria. In Canada, an individual was recently tested positive after a trip from that west African country back to British Columbia.
What does this growing array of variants do for mass vaccination schemes? Perhaps a new approach to sequencing and global coordination and collaboration is needed?
TrialSite News’ network of community members send their thoughts frequently and increasingly many call for collective, coordinated and orchestrated battle plans worldwide that includes not only vaccines and advanced pharmaceuticals but also low cost, economical repurposed drugs, some of which increasingly show promise.
Matthew Cotton, MRC/UVRI & LSHTM Uganda Research Unit, Entebbe Uganda and MRC-University of Glasgow Centre for Virus Research